

PharmLabs San Diego Certificate of Analysis



Sample **D8:HHC:THCP/B/H Blend**

Delta9 THC **UI** THCa **14.68%** Total THC(THCa * 0.877 + THC) **45.3%** Delta8 THC **32.16%**

Sample ID SD231212	Matrix Concentrate
Tested for Hemp and Tea Company	
Sampled -	Received Oct 16, 2024
Analyses executed CANx	Reported Oct 18, 2024

Laboratory note: The estimated concentration of the unknown peak in the sample is 5.4% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)δ8-THC or δ9-THC. At this time there are no reference standards available for (+)δ8-THC. (+)δ8-THC is a different compound from the main (-)δ8-THC cannabinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)δ8-THC and δ9-THC is problematic for the scientific community as a whole. PharmLabs believes the unidentified peak to be a combination of (+)δ8-THC and δ9-THC with the majority, if not all, of the concentration being (+)δ8-THC. | The estimated total δ8-THC concentration is 59.5%.

CANx - Cannabinoids Analysis

Analyzed **Oct 18, 2024** | Instrument **HPLC-VWD** | Method **SOP-001**
 The expanded Uncertainty of the Cannabinoid analysis is approximately **±.806%** at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THCV)	0.013	0.041	NT	NT
Cannabidiol (CBD)	0.002	0.007	NT	NT
Abnormal Cannabidiol (a-CBDO)	0.01	0.031	NT	NT
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.012	0.036	NT	NT
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.007	0.021	NT	NT
Cannabidiolic Acid (CBDA)	0.001	0.16	ND	ND
Cannabigerol Acid (CBGA)	0.001	0.16	ND	ND
Cannabigerol (CBG)	0.001	0.16	ND	ND
Cannabidiol (CBD)	0.001	0.16	ND	ND
1(S)-Tetrahydrocannabinol (1(S)-H4-CBD)	0.013	0.041	NT	NT
1(R)-Tetrahydrocannabinol (1(R)-H4-CBD)	0.025	0.075	NT	NT
Tetrahydrocannabinol (THCV)	0.001	0.16	ND	ND
Δ8-tetrahydrocannabinol (Δ8-THCV)	0.021	0.064	NT	NT
Cannabidihexol (CBDH)	0.005	0.16	NT	NT
Tetrahydrocannabinol (Δ9-THCB)	0.013	0.038	2.17	21.70
Cannabinol (CBN)	0.001	0.16	0.12	1.17
Cannabidiphorol (CBDP)	0.015	0.047	NT	NT
exo-THC (exo-THC)	0.005	0.16	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.003	0.16	UI	UI
Δ8-tetrahydrocannabinol (Δ8-THC)	0.004	0.16	32.16	321.59
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.126	0.42	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.16	11.13	111.30
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.118	0.39	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.16	29.04	290.42
Tetrahydrocannabinolic Acid (THCA)	0.001	0.16	14.68	146.79
Δ9-Tetrahydrocannabinol (Δ9-THCH)	0.024	0.071	2.11	21.09
Cannabinol Acetate (CBNO)	0.014	0.043	NT	NT
Δ9-Tetrahydrocannabinophorol (Δ9-THCP)	0.017	0.16	1.17	11.68
Δ8-Tetrahydrocannabinophorol (Δ8-THCP)	0.041	0.16	3.34	33.42
Cannabicitran (CBT)	0.005	0.16	NT	NT
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.16	NT	NT
9(S)-HHCP (s-HHCP)	0.031	0.094	NT	NT
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.16	NT	NT
9(R)-HHCP (r-HHCP)	0.026	0.079	NT	NT
9(S)-HHC-O-acetate (s-HHCO)	0.005	0.16	NT	NT
9(R)-HHC-O-acetate (r-HHCO)	0.008	0.025	NT	NT
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.067	0.204	NT	NT
Δ9-THC methyl ether (Δ9-MeO-THC)	0.029	0.088	NT	NT
Δ8-THC methyl ether (Δ8-MeO-THC)	0.001	0.002	NT	NT
Cannabichromene (CBC)	0.002	0.16	ND	ND
Cannabidivarin (CBDV)	0.039	0.16	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			13.14	131.37
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			45.30	452.96
Total CBD (CBDA * 0.877 + CBD)			ND	ND
Total CBG (CBGA * 0.877 + CBG)			ND	ND
Total HHC (9r-HHC + 9s-HHC)			40.17	401.70
Total Cannabinoids Analyzed			96.54	965.42

UI Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >ULOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



DCC license: **C8-0000098-LIC**
 DEA license: **RP0611043**
 ISO/IEC 17025:2017 Acc. L17-427-1

Authorized Signature

Brandon Starr

Brandon Starr, Quality Assurance Manager
 Fri, 18 Oct 2024 15:45:58 -0700

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1



*This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.